Anthera Pharmaceuticals Inc (ANTH) has 35 open-market insider trades by 19 insiders since 2010. The most active filer is OrbiMed Capital GP IV LLC, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| OrbiMed Capital GP IV LLC | Dir | — | 5 | $6.3M | 2013-01-30 |
| Orbimed Advisors LLC | Dir | — | 3 | $5.4M | 2013-01-25 |
| Venture Partners Iv Q. Lp Vantagepoint | 10% | — | 1 | $4.8M | 2011-05-05 |
| Samuel D. Isaly | Dir | — | 4 | $2.8M | 2012-06-29 |
| Vantagepoint Venture Partners IV Principals FUND L.P. | 10% | — | 3 | $2.1M | 2011-06-16 |
| A. Rachel Leheny | Dir | — | 1 | $750K | 2010-09-24 |
| James Healy | Dir | — | 2 | $474K | 2012-01-28 |
| Venture Partners Vi GmbH & Co. Kg Sofinnova | 10% | — | 1 | $318K | 2011-12-22 |
| Alain Azan | 10% | — | 1 | $156K | 2011-12-30 |
| Colin Hislop | Chief Medical Officer | — | 3 | $130K | 2015-11-13 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| John Craig Thompson | President | Buy | $11K | 2017-09-20 |
| Paul F. Truex | Director | Buy | $7K | 2017-09-07 |
| Colin Hislop | Chief Medical Officer | Sell | $66K | 2015-11-13 |
| Colin Hislop | Chief Medical Officer | Sell | $27K | 2015-11-11 |
| Debra Odink | CTO | Sell | $7K | 2015-10-12 |
| David E. Thompson | Director | Buy | $53K | 2013-06-24 |
Companies that share insiders with ANTH, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Bogdan Dziurzynski | Director | Buy | $6K | 2013-05-31 |
| OrbiMed Capital GP IV LLC | Director | Buy | $3.8M | 2013-01-30 |
| Orbimed Advisors LLC | Director | Buy | $1.1M | 2013-01-25 |
| Christopher S. Henney | Director | Buy | $75K | 2012-06-29 |
| Paul F. Truex | President | Buy | $15K | 2012-06-29 |
| Samuel D. Isaly | Director | Sell | $937K | 2012-06-29 |
| Orbimed Advisors LLC | Director | Sell | $3.8M | 2012-03-20 |
| Debra Odink | CTO | Sell | $13K | 2012-03-01 |
| Paul F. Truex | President | Sell | $118K | 2012-02-15 |